Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin’s lymphoma: A prospective study of 46 cases
Open Access
- 6 June 2014
- journal article
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 2 (5) , 695-700
Abstract
The treatment of T-cell non-Hodgkin's lymphoma (T‑NHL) remains challenging. There is currently no standard regimen for the treatment of T-NHL in the first‑ or second‑line setting. thalidomide was previously shown to exert antitumor effects through inhibiting angiogenesis, promoting apoptosis and immunomodulatory activity. However, all the previous studies on the treatment of lymphoma with thalidomide included patient samples of limited size. In the present study, 46 cases of eligible T-NHL patients were randomized into i) the control group (conventional combined chemotherapy, n=22) and ii) the thalidomide group (thalidomide plus combined chemotherapy, n=24). the median dose of thalidomide was 200 mg (range, 150‑400 mg) every night, without reported severe side effects. The clinical response to treatment was as follows: Complete response (CR) in 12 cases, partial response (PR) in 7, stable disease (SD) in 1 and progressive disease (PD) in 4 cases in the thalidomide group; and CR in 8 cases, PR in 6, SD in 3 and PD in 5 cases in the control group. The CR rate was 50.0 and 36.4% in the thalidomide and the control groups, respectively (P<0.05). The median progression‑free and overall survival were 12 and undefined months, respectively, in the thalidomide group and 6 and 17 months, respectively, in the control group. The toxicity profile was considered acceptable in both groups. Our results indicated that thalidomide plus combined chemotherapy may exhibit enhanced efficacy in the clinical treatment of T-NHL. In addition, this type of treatment may reduce the frequency of adverse gastrointestinal reactions and help alleviate fear of chemotherapy. Therefore, thalidomide plus combined chemotherapy may be a viable option for the clinical treatment of T-NHL.Keywords
This publication has 37 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patientsCancer Chemotherapy and Pharmacology, 2011
- Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC)American Journal of Physiology-Gastrointestinal and Liver Physiology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in gliomaMolecular Cancer Therapeutics, 2008
- Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide dosesEuropean Journal of Haematology, 2008
- Thalidomide therapy induces response in relapsed mantle cell lymphomaLeukemia, 2003
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Effect of Thalidomide on Apoptosis of Lymphocytes and NeutrophilsImmunopharmacology and Immunotoxicology, 1997
- Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential usesJournal of the American Academy of Dermatology, 1996